

Global Glucagon-like Peptide 1 (GLP-1)
Market: Analysis By Product (Trulicity,
Ozempic, Victoza, Rybelsus and Other GLP 1
Products), By Route of Administration
(Injectable and Oral Medication), By Region
Size and Trends with Impact of COVID-19
and Forecast up to 2027

January 2023



Global Glucagon-like Peptide 1 (GLP-1) Market: Coverage

Executive Summary and Scope

Introduction/Market Overview

Global Market Analysis

Regional Market Analysis

Impact of COVID

Dynamics

Competitive Landscape

Company Profiling

Global Glucagon-like Peptide 1 (GLP-1) Market: Coverage

Scope of the Report

Attributes	Details
Title	Global Glucagon-like Peptide 1 (GLP-1) Market: Analysis By Product (Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products), By Route of Administration (Injectable and Oral Medication), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027
Coverage	Global and Regional
Market Influencing Variables	Growth Drivers, Challenges, Market Trends
Forecast Period of Market	2022-2027
Competition in the Market	Moderately Concentrated
Key Players	Sanofi, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Shanghai Benemae Pharmaceutical Corporation, Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Global Glucagon-like Peptide 1 (GLP-1) Market: Coverage

Executive Summary

GLP-1, a major incretin hormone, is released from the gut in response to nutrients and stimulates glucose-induced insulin secretion potently. Its secretion is reduced in type 2 diabetes patients (1-4), and incretin-based therapies have emerged as a major therapeutic option. GLP-1 receptor activation regulates blood glucose concentrations through mechanisms such as increased insulin synthesis/secretion, decreased glucagon secretion, slowed gastric emptying, and increased satiety. The Global Glucagon-like Peptide 1 (GLP-1) market in 2021 stood at US\$16.53 billion, and is likely to reach US\$24.10 billion by 2027.


The glucagon-like peptide 1 (GLP-1) market can be segmented on the basis of product (trulicity, ozempic, victoza, rybelsus and other GLP 1 Products); route of administration (injectable and oral medication). On the basis of product, rybelsus segment is the fastest growing segment during forecast period, attributable to its effectiveness in lowering blood sugar levels, its convenient once-daily dosing, and the fact that it is taken orally rather than by injection like many other diabetes medications. Whereas, trulicity segment held majority of the market share in 2021 in global glucagon-like peptide 1 (GLP-1) market, owing to increasing prevalence of type 2 diabetes, which has led to a greater demand for effective treatments. North America is leading global glucagon-like peptide 1 (GLP-1) market by occupying more than one-third of the market share.

The COVID-19 pandemic has had a complex and multifaceted impact on the market for GLP-1 (glucagon-like peptide-1) drugs, which are used to treat type 2 diabetes by helping to control blood sugar levels. The demand for GLP-1 drugs may have increased as a result of the pandemic due to the high prevalence of diabetes and the associated risk of severe illness or death from COVID-19. People with diabetes are at increased risk of complications from COVID-19, including severe illness and death, and may therefore be more motivated to take their medications as prescribed and to manage their blood sugar levels carefully.

The global glucagon-like peptide 1 (GLP-1) market has increased in 2021 and projections are made that the market would rise in the next five years i.e. 2022-2027 tremendously. Rising cases of diabetes, rising cases of obesity, rapid urbanization, increasing healthcare expenditure, increasing aging population are some of the driver of the market. Further, the market is expected to grow owing to increasing in potential clinical application of GLP-1 receptor agonists for the treatment of NASH, surge in research & development in pharmaceutical sector, new product launches, expanding reimbursement landscape, etc. in recent years, yet the market faces some challenges such as short half-life of glucagon-like peptide 1 (GLP-1) receptor agonists, unknown severe side effects, etc.

Glucagon-like Peptide 1 (GLP-1) Market: Global Analysis

Global Glucagon-like Peptide 1 (GLP-1) Market by Value




CAGRs	
2017-2021	xx%
2022-2027	xx%

The global glucagon-like peptide 1 (GLP-1) market valued at US\$.... billion in 2021, increased as compared to US\$... billion in 2020. Global glucagon-like peptide 1 (GLP-1)market is anticipated to reach up to US\$... billion by 2027, at a CAGR of%, from US\$... billion in 2022.

Glucagon-like Peptide 1 (GLP-1) Market: Global Analysis

Global Glucagon-like Peptide 1 (GLP-1) Market by Product; 2021



Product	Share
Trulicity	xx%
Ozempic	xx%
Victoza	xx%
Rybelsus	xx%
Other GLP 1 Products	xx%


Global Glucagon-like Peptide 1 (GLP-1) Market by Route of Administration; 2021



Route of Administration	Share
Injectable	xx%
Oral Medication	xx%

Glucagon-like Peptide 1 (GLP-1) Market: Global Analysis


Global Glucagon-like Peptide 1 (GLP-1) Market by Regions; 2021




Regions	Share
North America	xx%
Europe	xx%
Asia Pacific	xx%
Latin America	xx%
Middle East and Africa	xx%

Global Glucagon-like Peptide 1 (GLP-1) Market: Product Analysis

Global Trulicity Market by Value




Global Ozempic Market by Value



Product	CAGR (2017-2021)	CAGR (2022-2027)
Trulicity	xx%	xx%
Ozempic	xx%	xx%
Victoza	xx%	xx%
Rybelsus	xx%	xx%
Other GLP 1 Products	xx%	xx%


Glucagon-like Peptide 1 (GLP-1) Market: Regional Analysis

North America Glucagon-like Peptide 1 (GLP-1) Market by Value




Regions	CAGR (2017-2021)	CAGR (2022-2027)
North America	xx%	xx%
Europe	xx%	xx%
Asia Pacific	xx%	xx%
Latin America	xx%	xx%
Middle East and Africa	xx%	xx%

Asia Pacific Glucagon-like Peptide 1 (GLP-1) Market by Value



North America Glucagon-like Peptide 1 (GLP-1) Market: Analysis

North America Glucagon-like Peptide 1 (GLP-1) Market by Region; 2021



The US Glucagon-like Peptide 1 (GLP-1) Market by Route of Administration; 2021



Region	Share	CAGR (2017-2021)	CAGR (2022-2027)
The US	xx%	xx%	xx%
Canada	xx%	xx%	xx%
Mexico	xx%	xx%	xx%


Route of Administration	Share
Injectable	xx%
Oral Medication	xx%

Asia Pacific Glucagon-like Peptide 1 (GLP-1) Market: Analysis

Asia Pacific Glucagon-like Peptide 1 (GLP-1) Market by Region; 2021



China Glucagon-like Peptide 1 (GLP-1) Market by Value




Region	Share	CAGR (2022-2027)
China	xx%	xx%
Japan	xx%	xx%
India	xx%	xx%
Australia	xx%	xx%
South Korea	xx%	xx%
Rest of Asia Pacific	xx%	xx%

Europe Glucagon-like Peptide 1 (GLP-1) Market: Analysis

Europe Glucagon-like Peptide 1 (GLP-1) Market by Region; 2021




Germany Glucagon-like Peptide 1 (GLP-1) Market by Value



Region	Share	CAGR (2022-2027)
Germany	xx%	xx%
UK	xx%	xx%
France	xx%	xx%
Italy	xx%	xx%
Spain	xx%	xx%
Rest of Europe	xx%	xx%

Global Glucagon-like Peptide 1 (GLP-1) Market: Dynamics



Global Glucagon-like Peptide 1 (GLP-1) Market: Competitive Landscape

Players Profiled

- Sanofi,
- Pfizer Inc.,
- AstraZeneca PLC,
- Eli Lilly and Company,
- Novo Nordisk A/S,
- Shanghai Benemae Pharmaceutical Corporation,
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Europe Glucagon-like Peptide 1 (GLP-1) Players by Market Share; 2021

